“…IL‐6 was the most focused inflammatory biomarker for OSA (Chu & Li, ; Kaditis et al, ; Kurt, Tosun, & Talay, ; Lopez‐Pascual et al, ; Popko et al, ; Shalitin, Deutsch, & Tauman, ; Wu et al, ; Zhong, Xiong, Shi, & Xu, ). IL‐6 rs1800796, a function variant located in the promoter region of IL‐6 , has been evaluated for its association with many kinds of diseases, including cancers, celiac disease, chronic HBV infection, acute coronary syndrome, ischemic stroke, periodontitis, IgA nephropathy, hip fracture, osteoarthritis, acute chorioamnionitis, etc., (Akinyemi et al, ; Amr, El‐Awady, & Raslan, ; Barartabar et al, ; Du, Gao, Zhang, & Wang, ; Eftekhari et al, ; Fernandes et al, ; Fragoso et al, ; Kaditis et al, ; Konwar, Del Gobbo, Terry, & Robinson, ; Li et al, ; Ponce de Leon‐Suarez et al, ; Tang et al, ; Wang, Chen, Zhao, Zhang, & Yu, ; Wang et al, ; Zhang et al, ; Zhang, Mao, & Sun, ; Zhao, Li, & Li, ). Although two previous studies evaluated the associations of IL‐6 rs1800796 with the development of OSA, the results were not significant, which may be caused by the relatively small sample size (Kaditis et al, ; Zhang et al, ).…”